About Depomed (NASDAQ:DEPO)
Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Generic Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:DEPO
- CUSIP: 24990810
- Web: www.depomedinc.com
- Market Cap: $339.51 million
- Outstanding Shares: 62,988,000
- 50 Day Moving Avg: $5.87
- 200 Day Moving Avg: $9.04
- 52 Week Range: $4.93 - $24.09
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.98
- P/E Growth: 0.47
- Annual Revenue: $425.34 million
- Price / Sales: 0.80
- Book Value: $3.36 per share
- Price / Book: 1.60
- EBITDA: $112.64 million
- Net Margins: -26.02%
- Return on Equity: -45.03%
- Return on Assets: -9.34%
- Debt-to-Equity Ratio: 2.71%
- Current Ratio: 0.79%
- Quick Ratio: 0.75%
- Average Volume: 1.67 million shs.
- Beta: 1.19
- Short Ratio: 8.72
Frequently Asked Questions for Depomed (NASDAQ:DEPO)
What is Depomed's stock symbol?
Depomed trades on the NASDAQ under the ticker symbol "DEPO."
How were Depomed's earnings last quarter?
Depomed, Inc. (NASDAQ:DEPO) announced its earnings results on Monday, August, 7th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.09 by $0.52. The business had revenue of $100 million for the quarter, compared to the consensus estimate of $100.40 million. Depomed had a negative return on equity of 45.03% and a negative net margin of 26.02%. Depomed's revenue for the quarter was down 14.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.27 EPS. View Depomed's Earnings History.
When will Depomed make its next earnings announcement?
Where is Depomed's stock going? Where will Depomed's stock price be in 2017?
9 brokers have issued 1 year price targets for Depomed's stock. Their forecasts range from $5.00 to $24.00. On average, they anticipate Depomed's stock price to reach $12.67 in the next year. View Analyst Ratings for Depomed.
What are analysts saying about Depomed stock?
Here are some recent quotes from research analysts about Depomed stock:
- 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
- 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)
Who are some of Depomed's key competitors?
Some companies that are related to Depomed include AC Immune SA (ACIU), Meridian Bioscience (VIVO), AxoGen (AXGN), Almost Family (AFAM), BeyondSpring (BYSI), MacroGenics (MGNX), AngioDynamics (ANGO), Paratek Pharmaceuticals (PRTK), WAVE Life Sciences (WVE), Synergy Pharmaceuticals (SGYP), ARGENX SE-ADR (ARGX), Voyager Therapeutics (VYGR), Celyad SA (CYAD), ImmunoGen (IMGN), TG Therapeutics (TGTX), Triple-S Management Corporation (GTS), Achaogen (AKAO) and Calithera Biosciences (CALA).
Who are Depomed's key executives?
Depomed's management team includes the folowing people:
- James P. Fogarty CPA, Chairman of the Board
- Arthur J. Higgins, President, Chief Executive Officer, Director
- August J. Moretti, Chief Financial Officer, Senior Vice President
- Matthew M. Gosling, Senior Vice President, General Counsel
- Sharon D. Larkin, Senior Vice President - Human Resources and Administration.
- Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality
- Karen A. Dawes, Independent Director
- Louis J. Lavigne Jr., Independent Director
- William T. McKee CPA, Independent Director
- Gavin T. Molinelli, Independent Director
How do I buy Depomed stock?
Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Depomed's stock price today?
MarketBeat Community Rating for Depomed (NASDAQ DEPO)MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Depomed stock can currently be purchased for approximately $5.39.
Consensus Ratings for Depomed (NASDAQ:DEPO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 5 Hold Ratings, 3 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.22)|
|Consensus Price Target: ||$12.67 (135.00% upside)|Consensus Price Target History for Depomed (NASDAQ:DEPO)
Analysts' Ratings History for Depomed (NASDAQ:DEPO)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/20/2017||Royal Bank Of Canada||Set Price Target||Hold||$10.00||N/A|
|10/15/2017||Piper Jaffray Companies||Set Price Target||Hold||$9.00||N/A|
|10/13/2017||Mizuho||Reiterated Rating||Neutral||$11.00 -> $6.00||N/A|
|8/8/2017||Morgan Stanley||Downgrade||Equal Weight -> Underweight||$12.00 -> $5.00||High|
|8/8/2017||Janney Montgomery Scott||Downgrade||Buy -> Neutral||$18.00 -> $8.00||High|
|5/15/2017||Cantor Fitzgerald||Set Price Target||Hold||$14.00||Medium|
|3/30/2017||JMP Securities||Reiterated Rating||Outperform||$30.00 -> $16.00||High|
|2/18/2017||Roth Capital||Set Price Target||Buy||$24.00||N/A|
|11/8/2016||Leerink Swann||Set Price Target||Buy||$22.00||N/A|
|3/24/2016||Northland Securities||Initiated Coverage||Outperform||$22.00||N/A|
|2/24/2016||WallachBeth Capital||Lower Price Target||Buy||$33.00 -> $27.00||N/A|
Earnings History for Depomed (NASDAQ:DEPO)Earnings History by Quarter for Depomed (NASDAQ DEPO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2017||Q2 2017||$0.09||($0.43)||$100.40 million||$100.00 million||View||Listen|
|5/9/2017||Q1 2017||($0.25)||($0.43)||$99.48 million||$95.00 million||View||Listen|
|2/21/2017||Q4 2016||$0.36||$0.48||$123.00 million||$123.90 million||View||Listen|
|11/7/2016||Q3||$0.35||$0.28||$127.22 million||$111.00 million||View||Listen|
|8/3/2016||Q2||$0.26||$0.27||$118.20 million||$116.70 million||View||Listen|
|5/5/2016||Q1||$0.17||$0.12||$106.88 million||$104.60 million||View||Listen|
|2/22/2016||Q415||$0.29||$0.16||$110.19 million||$111.20 million||View||Listen|
|11/9/2015||Q3||$0.19||$0.33||$101.64 million||$105.00 million||View||Listen|
|7/29/2015||Q215||($0.45)||$0.27||$88.33 million||$94.30 million||View||Listen|
|5/11/2015||Q115||$0.07||($0.13)||$33.80 million||$31.70 million||View||Listen|
|2/23/2015||Q414||$0.07||$0.21||$44.66 million||$33.90 million||View||Listen|
|11/5/2014||Q314||($0.04)||($0.01)||$41.50 million||$51.49 million||View||Listen|
|8/6/2014||Q214||($0.06)||($0.03)||$38.03 million||$67.70 million||View||Listen|
|5/8/2014||Q114||$0.11||($0.04)||$53.57 million||$76.50 million||View||Listen|
|3/12/2014||Q413||($0.21)||$0.72||$19.06 million||$40.60 million||View||Listen|
|11/5/2013||Q313||$0.07||$0.11||$35.55 million||$37.50 million||View||Listen|
|8/7/2013||Q2 2013||($0.05)||$0.01||$29.87 million||$30.00 million||View||Listen|
|5/8/2013||Q1 2013||($0.06)||($0.10)||$28.93 million||$26.20 million||View||Listen|
|2/20/2013||Q4 2012||($0.11)||($0.07)||$26.48 million||$26.60 million||View||Listen|
|11/5/2012||Q312||($0.11)||($0.03)||$28.06 million||$33.30 million||View||N/A|
Earnings Estimates for Depomed (NASDAQ:DEPO)
2017 EPS Consensus Estimate: ($0.20)
2018 EPS Consensus Estimate: $0.38
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Depomed (NASDAQ:DEPO)
Insider Ownership Percentage: 2.59%Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Institutional Ownership Percentage: 91.25%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/12/2017||Arthur J Higgins||Insider||Buy||15,000||$9.92||$148,800.00|| |
|11/14/2016||August J Moretti||CFO||Sell||5,000||$20.84||$104,200.00|| |
|9/21/2016||Thadd M Vargas||VP||Sell||11,250||$25.00||$281,250.00|| |
|8/10/2016||August J. Moretti||CFO||Sell||5,000||$21.40||$107,000.00|| |
|8/10/2016||Thadd M Vargas||VP||Sell||26,290||$20.92||$549,986.80|| |
|5/23/2016||Thadd M Vargas||VP||Sell||15,000||$20.00||$300,000.00|| |
|5/10/2016||Thadd M Vargas||VP||Sell||15,000||$17.64||$264,600.00|| |
|5/9/2016||August J Moretti||CFO||Sell||5,000||$18.00||$90,000.00|| |
|3/11/2016||Thadd M Vargas||VP||Sell||23,000||$16.00||$368,000.00|| |
|12/3/2015||August J. Moretti||CFO||Sell||15,000||$18.11||$271,650.00|| |
|6/12/2015||Thadd M Vargas||VP||Sell||5,000||$20.70||$103,500.00|| |
|12/2/2014||August J Moretti||CFO||Sell||5,339||$15.85||$84,623.15|| |
|12/2/2014||James A Schoeneck||CEO||Sell||36,727||$15.85||$582,122.95|| |
|12/2/2014||Thadd M Vargas||VP||Sell||8,247||$15.85||$130,714.95|| |
|11/19/2014||Matthew M Gosling||VP||Sell||71,000||$15.36||$1,090,560.00|| |
|3/14/2014||James Schoeneck||CEO||Sell||17,000||$14.54||$247,180.00|| |
|3/14/2014||Matthew Gosling||VP||Sell||21,875||$14.74||$322,437.50|| |
|12/2/2013||Michael Md Sweeney||CMO||Sell||4,270||$8.40||$35,868.00|| |
|12/2/2013||Thadd Vargas||VP||Sell||5,296||$8.40||$44,486.40|| |
|5/10/2013||James A Schoeneck||CEO||Buy||25,000||$5.11||$127,750.00|| |
|3/6/2013||Karen A Dawes||Director||Buy||2,000||$5.96||$11,920.00|| |
|8/14/2012||Peter D Staple||Director||Buy||5,000||$5.01||$25,050.00|| |
Headline Trends for Depomed (NASDAQ:DEPO)
Latest Headlines for Depomed (NASDAQ:DEPO)
Loading headlines, please wait.
Depomed (DEPO) Chart for Sunday, October, 22, 2017